VCID Biomarker's Coordinating Center

项目摘要/摘要 脑部小血管疾病所致认知损害和痴呆的血管贡献 (SVD)现在被认为是一个主要的公共卫生威胁。响应NINDS对多站点的调用 致力于识别和验证SVD相关VCID的生物标记物的财团，我们建议成立 马萨诸塞州总医院(MGH)VCID生物标志物协调中心。建议的目标是 协调中心将提供杰出的科学领导和最先进的管理和 VCID生物标志物联盟的数据管理基础设施。拟议的MGH的具体优势 协调中心包括1)首席调查员作为科学先驱展示的高水平技能 SVD生物标志物和复杂多中心项目和组织的有效领导者，2)杰出的 由管理和数据核心主管、合作调查人员和研究人员组成的经验丰富的团队能够 处理复杂协调中心的方方面面，3)多模式数据处理的创新方法 将MRI数据中的扫描仪间差异降至最低，以及4)制定详细的组织计划，以实现高效的高级别 由代表委员会作出决策，制定数据收集联合体标准和 分享、联盟范围内的沟通，以及与相关外部努力的联系。如果选中，则建议的 MGH协调中心将处于领导财团实现其移动SVD目标的理想位置 VCID临床试验前沿的生物标记物。

PROJECT SUMMARY/ABSTRACT The vascular contribution to cognitive impairment and dementia (VCID) driven by cerebral small vessel disease (SVD) is now recognized as a major public health threat. In response to the call from NINDS for a multisite consortium dedicated to identifying and validating biomarkers for SVD-related VCID, we propose to form the Massachusetts General Hospital (MGH) VCID Biomarkers Coordinating Center. The aims of the proposed coordinating center will be to provide outstanding scientific leadership and state-of-the-art administrative and data management infrastructure to the VCID biomarkers consortium. Specific strengths of the proposed MGH coordinating center include 1) the Principal Investigator's demonstrated high-level skill as a scientific pioneer in SVD biomarkers and an effective leader of complex multicenter projects and organizations, 2) an outstanding and experienced team of Administrative and Data Core directors, co-Investigators, and study staff capable of handling all aspects of a complex coordinating center, 3) innovative approaches to multimodal data handling and minimizing inter-scanner variations in MRI data, and 4) detailed organizational plans for efficient high-level decision-making by representative committees, creation of consortium standards for data collection and sharing, consortium-wide communication, and outreach to related external efforts. If selected, the proposed MGH coordinating center will be ideally positioned to lead the consortium to its goals of moving SVD biomarkers to the forefront of VCID clinical trials.